A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Chen, Shiuan, Ph.D. Bookmark and Share

Shiuan Chen, Ph.D. - Laboratory and Research Focus

Breast Cancer Translation Research

Shiuan Chen, Ph.D.,
was one of the three investigators who originally isolated the full-length human aromatase cDNA clones. Aromatase is an enzyme that converts androgen to estrogen. Aromatase inhibitors (AIs) are important drugs to treat estrogen-dependent breast cancer. Approximately 60percent of premenopausal and 75 percent of postmenopausal breast cancer patients have estrogen-dependent carcinomas. 
 
Since aromatase is the enzyme responsible for the synthesis of estrogen, and estrogen can have a major effect in the development of breast cancer, an abnormal expression of aromatase in breast cancer cells and/or surrounding adipose stromal cells may have a significant influence on breast tumor development and growth in cancer patients. Aromatase is expressed at higher levels in human breast cancer tissue than in normal breast tissue, as measured by various biochemical assays. During the last 15 years, aromatase inhibitors (AIs) have been demonstrated to be superior to tamoxifen for the treatment of hormonal dependent breast cancer. While this new generation of aromatase inhibitors is shown to be useful in the treatment of hormonal responsive breast cancer, resistance to such endocrine therapy still develops. Through collaboration with Yate-Ching Yuan, Ph.D., (Bioinformatics), we are carrying out gene expression array experiments on AI-responsive as well as resistant cell lines that have been generated in our laboratory. We are identifying and functionally confirming the roles of genes involved in resistance.
 
These studies will produce valuable molecular information regarding the mechanisms of AI resistance, and the information will help design approaches to reduce resistance and improve the efficacy of AI treatments of breast cancer. Furthermore, our model systems are valuable to test new drugs against endocrine therapy resistance. We are working with several medical and translational research colleagues (Joanne Mortimer, M.D. , Yuan Yuan, M.D., Ph.D., George Somlo, M.D., Laura Kruper, M.D., Courtney Vito, M.D.,Paul Frankel, Ph.D., Tim Synold, Pharm.D.), and Ned Newman, Ph.D. ) to carry preclinical studies in our laboratories and then to design new therapeutic approaches to treat AI resistant breast cancer.
 
Chemoprevention and Superfood Research Program

Since the summer of 2004, Chen and 27 other investigators have initiated an effort to develop a Chemoprevention Research Program at City of Hope. Through biweekly meetings, these Beckman Research Institute of City of Hope researchers and clinicians exchange research information and ideas. Four research areas have recently been chosen to focus on. The immediate goal is to generate preliminary results in these new target areas that will lead to the development of multidiscipline translational chemoprevention research projects at our institution.
 
Our laboratory has found that grapes, mushrooms and pomegranate contain chemicals that can suppress aromatase activity.  Therefore, a diet that includes grapes, mushrooms and pomegranate would be considered preventative against breast cancer.  We are purifying and characterizing these natural anti-aromatase chemicals and evaluating their in vivo effects using animal experiments. The active chemicals in grapes have been found to be procyanidin dimers that are present at high concentrations in grape seeds. Melanie Palomares, M.D., M.S., (Population Sciences), Jeffrey Weitzel, M.D., (Clinical Cancer Genetics), Tim Synold, Pharm.D., (Experimental Therapeutics) and this laboratory have collaborated and initiated a grape seed extract clinical trial and a mushroom clinical trial based on the chemoprevention studies against breast cancer performed in our laboratory. In addition, experiments have been carried out to show that blueberry contains phytochemicals that can suppress the proliferation and migration of triple negative breast cancer in cell culture and animals. Efforts are being made to initiate a blueberry clinical trial at City of Hope to support that there is scientific proof of breast cancer superfoods plus additional information on this subject, plus additional information on this subject, and still more
 
Furthermore, we have found that mushrooms contain chemicals that act as inhibitors of steroid 5-alpha reductase. Androgen plays a critical role in prostate cancer development.  In the prostate, testosterone (an androgen) is converted to dihydrotestosterone (DHT), an androgen that is even more potent than testosterone. This conversion is catalyzed by the enzyme steroid 5-alpha reductase. An elevation of the steroid 5-alpha reductase activity in the prostate may cause benign prostate hyperplasia (a common problem in older men) and also promote the growth of prostate cancer. Animal experiments have been performed to evaluate the use of these phytochemicals as drugs in the prevention and/or treatment of prostate cancer. One clinical trial designed, based Chen’s findings, is being carried out at City of Hope with Przemyslaw Twardowski, M.D. (Medical Oncology) to evaluate the protective effect of mushroom chemicals against PSA increase in prostate cancer patients. The trial has resulted in two patients with complete response, two patients with partial response, and eight patients with stable PSA response. A recent study in the Chen laboratory has revealed that the intake of mushrooms may reduce the incidence of metabolic diseases such as fatty liver and insulin resistance.
 
In 2014, with a $2.5 million gift from the Panda Charitable Foundation, a Program in Natural Therapies has been established at City of Hope. This fund supports three lines of research to investigate natural products’ abilities to fight against cancer. Chen is investigating how the foods themselves can improve outcomes of treatment-resistance breast cancer.  In addition, the Chen laboratory is generating patient-derived xenograft (PDX) models for novel treatment of breast cancer.
 
Endocrine Disruptor Research

We are also conducting research to determine how environmental chemicals modulate the activity and expression of aromatase in human tissue. Experiments are being conducted to provide a molecular and mechanistic basis as to how phytochemicals and organochlorine compounds affect estrogen biosynthesis (e.g., aromatase function) in women. Research from Chen’s and other laboratories have revealed that estrogen receptors (ER), aromatase, and ERR are key players in breast cancer promotion and in cancer recurrence following endocrine treatment. Furthermore, proof-of-concept studies have revealed that these proteins are targets of endocrine disruptors. Based on these observations, we hypothesize that environmental chemicals will play critical roles in modulating breast cancer through ER, aromatase and ERR. We have developed a high throughput screening system (AroER Tri-Screen™) for identifying chemicals targeting ER and aromatase. The goal of this research is to develop screening assays for identifying and testing chemicals with relevance to known and suspected causes of estrogen-dependent breast cancer. Our collaborators include Yate-Ching Yuan, Ph.D. (Bioinformatics Core), Xiwei Wu, M.D., Ph.D. (Integrative Genomics Core), Christina Teng, Ph.D. (National Institute of Environmental Health Sciences), Menghang Xia, Ph.D., and Ruiling Huang, Ph.D. (National Center for Advancing Translational Sciences), Sandra Finestone, Psy.D. (Hope Wellness Center, Costa Mesa, California) and Kimlin Tam Ashing, Ph.D. (Population Sciences). Furthermore, we are collaborating with Myrto Petreas, Ph.D. (California Department of Toxic Substances Control) and Peggy Reynolds, Ph.D. (Cancer Prevention Institute of California) for the evaluation of estrogenic activity in human serum using AroER Tri-Screen.
 
Learn more about Shiuan Chen, Ph.D.
 
 
 
 

Shiuan Chen, Ph.D. Lab Members

Hei (Jason) Chan, B.S.
Graduate Student
626-256-HOPE (4673), Ext. 63056
 
Nymph Chan, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Noriko Kanaya, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Duc Nguyen, B.S.
Research Associate
626-256-HOPE (4673), Ext. 63056
 
Karineh Petrossian, M.S.
Graduate Student
626-256-HOPE (4673), Ext. 65062
 
Yuan-Zhong Wang, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Shang Wu, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65061
 

Chen, Shiuan, Ph.D.

Shiuan Chen, Ph.D. - Laboratory and Research Focus

Breast Cancer Translation Research

Shiuan Chen, Ph.D.,
was one of the three investigators who originally isolated the full-length human aromatase cDNA clones. Aromatase is an enzyme that converts androgen to estrogen. Aromatase inhibitors (AIs) are important drugs to treat estrogen-dependent breast cancer. Approximately 60percent of premenopausal and 75 percent of postmenopausal breast cancer patients have estrogen-dependent carcinomas. 
 
Since aromatase is the enzyme responsible for the synthesis of estrogen, and estrogen can have a major effect in the development of breast cancer, an abnormal expression of aromatase in breast cancer cells and/or surrounding adipose stromal cells may have a significant influence on breast tumor development and growth in cancer patients. Aromatase is expressed at higher levels in human breast cancer tissue than in normal breast tissue, as measured by various biochemical assays. During the last 15 years, aromatase inhibitors (AIs) have been demonstrated to be superior to tamoxifen for the treatment of hormonal dependent breast cancer. While this new generation of aromatase inhibitors is shown to be useful in the treatment of hormonal responsive breast cancer, resistance to such endocrine therapy still develops. Through collaboration with Yate-Ching Yuan, Ph.D., (Bioinformatics), we are carrying out gene expression array experiments on AI-responsive as well as resistant cell lines that have been generated in our laboratory. We are identifying and functionally confirming the roles of genes involved in resistance.
 
These studies will produce valuable molecular information regarding the mechanisms of AI resistance, and the information will help design approaches to reduce resistance and improve the efficacy of AI treatments of breast cancer. Furthermore, our model systems are valuable to test new drugs against endocrine therapy resistance. We are working with several medical and translational research colleagues (Joanne Mortimer, M.D. , Yuan Yuan, M.D., Ph.D., George Somlo, M.D., Laura Kruper, M.D., Courtney Vito, M.D.,Paul Frankel, Ph.D., Tim Synold, Pharm.D.), and Ned Newman, Ph.D. ) to carry preclinical studies in our laboratories and then to design new therapeutic approaches to treat AI resistant breast cancer.
 
Chemoprevention and Superfood Research Program

Since the summer of 2004, Chen and 27 other investigators have initiated an effort to develop a Chemoprevention Research Program at City of Hope. Through biweekly meetings, these Beckman Research Institute of City of Hope researchers and clinicians exchange research information and ideas. Four research areas have recently been chosen to focus on. The immediate goal is to generate preliminary results in these new target areas that will lead to the development of multidiscipline translational chemoprevention research projects at our institution.
 
Our laboratory has found that grapes, mushrooms and pomegranate contain chemicals that can suppress aromatase activity.  Therefore, a diet that includes grapes, mushrooms and pomegranate would be considered preventative against breast cancer.  We are purifying and characterizing these natural anti-aromatase chemicals and evaluating their in vivo effects using animal experiments. The active chemicals in grapes have been found to be procyanidin dimers that are present at high concentrations in grape seeds. Melanie Palomares, M.D., M.S., (Population Sciences), Jeffrey Weitzel, M.D., (Clinical Cancer Genetics), Tim Synold, Pharm.D., (Experimental Therapeutics) and this laboratory have collaborated and initiated a grape seed extract clinical trial and a mushroom clinical trial based on the chemoprevention studies against breast cancer performed in our laboratory. In addition, experiments have been carried out to show that blueberry contains phytochemicals that can suppress the proliferation and migration of triple negative breast cancer in cell culture and animals. Efforts are being made to initiate a blueberry clinical trial at City of Hope to support that there is scientific proof of breast cancer superfoods plus additional information on this subject, plus additional information on this subject, and still more
 
Furthermore, we have found that mushrooms contain chemicals that act as inhibitors of steroid 5-alpha reductase. Androgen plays a critical role in prostate cancer development.  In the prostate, testosterone (an androgen) is converted to dihydrotestosterone (DHT), an androgen that is even more potent than testosterone. This conversion is catalyzed by the enzyme steroid 5-alpha reductase. An elevation of the steroid 5-alpha reductase activity in the prostate may cause benign prostate hyperplasia (a common problem in older men) and also promote the growth of prostate cancer. Animal experiments have been performed to evaluate the use of these phytochemicals as drugs in the prevention and/or treatment of prostate cancer. One clinical trial designed, based Chen’s findings, is being carried out at City of Hope with Przemyslaw Twardowski, M.D. (Medical Oncology) to evaluate the protective effect of mushroom chemicals against PSA increase in prostate cancer patients. The trial has resulted in two patients with complete response, two patients with partial response, and eight patients with stable PSA response. A recent study in the Chen laboratory has revealed that the intake of mushrooms may reduce the incidence of metabolic diseases such as fatty liver and insulin resistance.
 
In 2014, with a $2.5 million gift from the Panda Charitable Foundation, a Program in Natural Therapies has been established at City of Hope. This fund supports three lines of research to investigate natural products’ abilities to fight against cancer. Chen is investigating how the foods themselves can improve outcomes of treatment-resistance breast cancer.  In addition, the Chen laboratory is generating patient-derived xenograft (PDX) models for novel treatment of breast cancer.
 
Endocrine Disruptor Research

We are also conducting research to determine how environmental chemicals modulate the activity and expression of aromatase in human tissue. Experiments are being conducted to provide a molecular and mechanistic basis as to how phytochemicals and organochlorine compounds affect estrogen biosynthesis (e.g., aromatase function) in women. Research from Chen’s and other laboratories have revealed that estrogen receptors (ER), aromatase, and ERR are key players in breast cancer promotion and in cancer recurrence following endocrine treatment. Furthermore, proof-of-concept studies have revealed that these proteins are targets of endocrine disruptors. Based on these observations, we hypothesize that environmental chemicals will play critical roles in modulating breast cancer through ER, aromatase and ERR. We have developed a high throughput screening system (AroER Tri-Screen™) for identifying chemicals targeting ER and aromatase. The goal of this research is to develop screening assays for identifying and testing chemicals with relevance to known and suspected causes of estrogen-dependent breast cancer. Our collaborators include Yate-Ching Yuan, Ph.D. (Bioinformatics Core), Xiwei Wu, M.D., Ph.D. (Integrative Genomics Core), Christina Teng, Ph.D. (National Institute of Environmental Health Sciences), Menghang Xia, Ph.D., and Ruiling Huang, Ph.D. (National Center for Advancing Translational Sciences), Sandra Finestone, Psy.D. (Hope Wellness Center, Costa Mesa, California) and Kimlin Tam Ashing, Ph.D. (Population Sciences). Furthermore, we are collaborating with Myrto Petreas, Ph.D. (California Department of Toxic Substances Control) and Peggy Reynolds, Ph.D. (Cancer Prevention Institute of California) for the evaluation of estrogenic activity in human serum using AroER Tri-Screen.
 
Learn more about Shiuan Chen, Ph.D.
 
 
 
 

Lab Members

Shiuan Chen, Ph.D. Lab Members

Hei (Jason) Chan, B.S.
Graduate Student
626-256-HOPE (4673), Ext. 63056
 
Nymph Chan, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Noriko Kanaya, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Duc Nguyen, B.S.
Research Associate
626-256-HOPE (4673), Ext. 63056
 
Karineh Petrossian, M.S.
Graduate Student
626-256-HOPE (4673), Ext. 65062
 
Yuan-Zhong Wang, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Shang Wu, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65061
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • To say that myelofibrosis patients need more treatment options would be an understatement. The severely low platelet counts, known as thrombocytopenia, that are one of the hallmark symptoms of the disease can lead to chronic fatigue and weakness that not only damage quality of life but, ultimately, shorten life...
  • Patients with metastatic colorectal cancer often stop responding to the primary drugs used against the disease, leaving them with few options and little hope. Determined to increase those options, doctors and researchers at City of Hope are conducting two clinical trials that could lead to new treatments for pe...
  • Investigators working at City of Hope are making many significant inroads against many forms of cancer. To do that, they have to take a variety of approaches. Molecular oncology researchers focus on abnormal cancer-associated activity in a cell’s nucleus. One especially prominent factor in many breast and ovari...
  • In light of the new breast cancer screening guidelines, which call for women to have mammograms every other year from age 50 to 74, it’s more important than ever for women to understand their individual risk. On Monday, the U.S. Preventive Services Task force released new breast cancer screening guideline...
  • Cancer patients need, and deserve, more than medical care. They and their families need high-quality supportive care – that is, care that addresses their physical, emotional and spiritual well-being. Health care professionals increasingly understand this, but starting such programs from scratch isn’t easy...
  • Each year, City of Hope patients given another chance at life gather to pose for a picture like this one. Going on its 39th year, the celebration of patients free of blood cancers thanks to bone marrow or stem cell transplants has grown such that a photographer has to scale a cherry picker just to […]
  • Cancer patients who are participating in early-stage clinical trials need extra emotional and physical support due to their additional stress and often unique symptoms. Now an effort by researchers at City of Hope to create a model for such support has received a $6.8 million grant from the National Cancer Inst...
  • The need for improvements in treating malignant brain tumors has never been greater. Survival for many patients with these tumors are sometimes measured in just months. One reason that therapeutic options are limited is that traditional surgery is deemed too risky for many brain tumors, especially for those in ...
  • “Honestly, there’s nothing special about my story,” protested Daniel Samson, as he bounced Layla, his 3 1/2-year-old daughter, on his lap and put on a video for her to watch. “I just want to tell it for my own sake, and share it with other men who may be going through this chaos.” Samson spoke […]
  • As far back as he can remember, Jonathan Yamzon, M.D., wanted to be a doctor. “I knew it from the get-go,” he said, matter-of-factly. “I always envisioned it as the ideal; the supreme thing one could do with one’s life.” The youngest of six children, Yamzon was barely a toddler when his family moved to [&...
  • There’s never a “good” time for cancer to strike. With testicular cancer, the timing can seem particularly unfair. This disease targets young adults in the prime of life; otherwise healthy people unaccustomed to any serious illness, let alone cancer. And suddenly … “I can only imagine what they must...
  • Sure, a healthy lifestyle can lower a person’s risk, but the impact of specific actions is harder to tease out. Diet, exercise, tobacco use, nutritional supplements, alcohol consumption … How important are each of these factors, individually? Does strict adherence to (or rejection of) one get you a pass o...
  • Health care decisions are tough. They’re even tougher when you – or loved ones – have to make them without a plan or a conversation. National Healthcare Decisions Day, on April 16,  is a nationwide initiative to demystify the health care decision-making process and encourage families to start talking. Ult...
  • The statistics, direct from the American Cancer Society, are sobering: Cancer death rates among African-American men are 27 percent higher than for white men. The death rate for African-American women is 11 percent higher compared to white women. Hispanics have higher rates of cervical, liver and stomach cancer...
  • “Lucky” is not usually a term used to describe someone diagnosed with cancer.  But that’s how 34-year-old Alex Camargo’s doctor described him when he was diagnosed with thyroid cancer — the disease is one of the most treatable cancers at all stages. That doctor was ultimately proved righ...